NCT03818256 - A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

June 17, 2022

Study Completion Date

July 6, 2022

Conditions

Antipsychotic-induced Weight Gain (AIWG)

Interventions

DRUG

Miricorilant

Miricorilant 600 mg (6 X 100 mg tablets) for once-daily oral dosing

DRUG

Placebo

Placebo tablets for once-daily oral dosing

Trial Locations (27)

10032

Site 216, New York

19372

Site 235, Thorndale

19380

Site 235, West Chester

20161

Site 138, Glen Burnie

27608

Site 181, Raleigh

27610

Site 181, Raleigh

33122

Site 202, Miami

33161

Site 144, North Miami

34972

Site 241, Okeechobee

45417

Site 107, Dayton

60641

Site 140, Chicago

60712

Site 140, Lincolnwood

67214

Site 146, Wichita

72211

Site 249, Little Rock

72712

Site 143, Bentonville

75080

Site 165, Richardson

75115

Site 206, DeSoto

77030

Site 066, Houston

84105

Site 139, Salt Lake City

89102

Site 151, Las Vegas

90230

Site 153, Culver City

91730

Site 229, Rancho Cucamonga

91945

Site 134, Lemon Grove

92056

Site 163, Oceanside

92845

Site 239, Garden Grove

94607

Site 126, Oakland

98007

Site 137, Bellevue